-
WNT5a/GSK3/β-Catenin Control of FAP Adipogenesis
2026-09-15
The reference study identifies the WNT5a/GSK3/β-catenin axis as a major regulator of adipogenic drift in skeletal muscle fibro/adipogenic progenitors. By combining pharmacological screening, mass cytometry, animal models, network analysis, and transcriptomic datasets, it connects pathway activity with fatty degeneration and FAP support of muscle regeneration.
-
CAF–ANGPTL4-IQGAP1 Chemoresistance in Prostate Cancer
2026-09-15
The reference study identifies a paracrine ANGPTL4–IQGAP1 pathway through which cancer-associated fibroblasts reprogram prostate cancer mitochondrial metabolism and reduce chemotherapy sensitivity. Its integrated proteomic, metabolic, interaction, and pharmacological experiments position IQGAP1 and the CAF secretome as experimentally testable targets, while QGGP provides an initial small-molecule lead for combination strategies.
-
Protease Inhibitor Cocktail EDTA-Free Guide
2026-09-14
This scenario-based guide explains how Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO), SKU K1007, can protect protein endpoints associated with viability, proliferation, and cytotoxicity experiments. It covers compatibility with phosphorylation analysis, practical dilution and storage decisions, and criteria for selecting a reliable ready-to-use inhibitor formulation.
-
Reactive Oxygen Species Assay Kit for Live Cells
2026-09-14
Translate radiation, nanoparticle, and drug-induced oxidative stress into measurable live-cell fluorescence with a practical DCFH-DA workflow. The assay combines a defined positive control with decision-ready controls for radiosensitization, apoptosis, and cancer research oxidative stress studies.
-
NF 340: Mapping P2Y11 Signaling in Cancer
2026-09-13
Explore how the P2Y11 antagonist NF 340 can help separate receptor-dependent signaling from downstream effects in breast cancer invasion assays. This evidence-led guide translates QPRT–purinergic signaling findings into practical experimental decisions while defining limitations for immunology research.
-
EZH2 Inhibition in Fragile X Syndrome Neurons
2026-09-12
Fang and colleagues identify EZH2 as a functional contributor to FMR1 silencing and show that pharmacological or antisense inhibition can restore FMR1-related molecular and electrophysiological phenotypes in fragile X syndrome neurons. The work provides a mechanistic foundation for EZH2-directed reactivation strategies while highlighting blood–brain barrier penetration and delivery as major translational challenges.
-
Polymyxin B Sulfate: Mechanism and Research Use
2026-09-12
Polymyxin B sulfate is a cationic polypeptide antibiotic used in research on multidrug-resistant Gram-negative bacteria, membrane injury, immune signaling, and bacteremia. Its principal value is rapid membrane disruption, while nephrotoxicity, neurotoxicity, limited activity against many non-target organisms, and assay-specific immune effects define important boundaries.
-
Cyanin Chloride in a HaCaT Psoriasis Model
2026-09-11
A 2024 study examined cyanin chloride in chemical antioxidant assays, macrophage inflammation experiments, and a cytokine-induced HaCaT psoriasis model. Its main contribution was to connect reduced inflammatory signaling, STAT3 modulation, improved transepithelial resistance, and increased filaggrin expression, while leaving clinical efficacy and compound identity questions for further study.
-
GLT-1–CB1–CREB Signaling in Traumatic Brain Injury
2026-09-11
This 2025 Biomolecules study identifies a mechanistic link between elevated 2-AG, CB1-CREB signaling, reduced astrocytic GLT-1, and secondary neuronal injury after traumatic brain injury. Its pharmacological and behavioral data suggest that restoring glutamate clearance may reduce apoptosis and cognitive dysfunction, while also defining important limits for translation beyond mouse models.
-
GSH-Responsive MOF Nanoparticles for Melanoma Therapy
2026-09-10
Hao et al. developed ICG-MOF-SS-AUNP12, a zirconium-based metal–organic framework that combines near-infrared photothermal therapy with glutathione-responsive PD-1/PD-L1 blockade. The study shows how a redox-sensitive nanoplatform can couple tumor-cell heating with dendritic-cell maturation and immune activation, while also defining important considerations for translating related imaging dyes into therapeutic workflows.
-
Cathepsin B inhibitor CA-074: Practical Guide
2026-09-10
Cathepsin B inhibitor CA-074 (SKU A1926) is a biochemical and cell-study tool for testing cathepsin B-dependent proteolysis in cancer, neurodegeneration, and immune-response models. Its dossier supports selective enzyme inhibition and defined handling conditions, but it should not be treated as a universal cell-permeable probe or used to infer disease efficacy without model-specific controls.
-
TREM2, Microglia, and Autoimmune Uveitis
2026-09-09
A 2026 study identifies TREM2 as an anti-inflammatory regulator of microglia in experimental autoimmune uveitis, linking its activity to suppression of ERK/p38 signaling. The work combines mouse disease models, BV2-cell perturbation, immune phenotyping, and RNA sequencing to connect retinal inflammation with adaptive Th1, Th17, and Treg imbalance.
-
Amikacin (BAY416651) in CRE Resistance Research
2026-09-09
Amikacin (BAY416651) combines a defined bacterial protein synthesis mechanism with practical value in isolate-level resistance studies. Its strongest use-case is a mechanism-resolved workflow that connects susceptibility testing with carbapenemase genotyping, plasmid localization, and transmission analysis.
-
Clathrin-Mediated Entry of Type III Grass Carp Reovirus
2026-09-08
Wang et al. combined pharmacological inhibition, transmission electron microscopy, and quantitative PCR to define how genotype III grass carp reovirus enters cultured fish cells. Their results identify a dynamin-dependent, acidification-sensitive clathrin pathway and show that amiloride did not inhibit viral entry under the tested conditions, an important distinction for interpreting sodium channel and endocytosis experiments.
-
(R,S)-Anatabine in Amyloid Research
2026-09-08
Anatabine is a research compound that lowers amyloid-beta generation through reported effects on APP beta-cleavage and BACE-1 expression. (R,S)-Anatabine supports controlled in vitro and in vivo Alzheimer's disease model workflows, but the available dossier does not establish clinical efficacy or a direct catalytic BACE-1 binding mechanism.